Matrix metalloproteinase-2 plays a critical role in the pathogenesis of white matter lesions after chronic cerebral hypoperfusion in rodents

Stroke

Volumn 37, Issue 11, 2006, Pages 2816-2823

  Nakaji, Kayoko ^a,c   Ihara, Masafumi ^a   Takahashi, Chiaki ^a   Itohara, Shigeyoshi ^b   Noda, Makoto ^a   Takahashi, Ryosuke ^a   Tomimoto, Hidekazu ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Blood brain barrier; Chronic cerebral hypoperfusion; MMP inhibitor; MMP 2; White matter lesion

Indexed keywords

EVANS BLUE; GELATINASE A; MATRIX METALLOPROTEINASE INHIBITOR; PRINOMASTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN DAMAGE; BRAIN PERFUSION; CELL ACTIVATION; COGNITIVE DEFECT; CONTRAST MEDIUM EXTRAVASATION; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; IMMUNOHISTOCHEMISTRY; KNOCKOUT GENE; MACROGLIA; MALE; MEMBRANE DAMAGE; MICROGLIA; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; UPREGULATION; WHITE MATTER; ANIMAL; BRAIN; C57BL MOUSE; CHRONIC BRAIN DISEASE; COMPARATIVE STUDY; DRUG ANTAGONISM; ENZYMOLOGY; HOSPITALIZATION; MOUSE MUTANT; MYELINATED NERVE; PATHOLOGY; PHYSIOLOGY; VASCULARIZATION; WISTAR RAT;

ANIMALS; BRAIN; BRAIN DAMAGE, CHRONIC; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE FIBERS, MYELINATED; RATS; RATS, WISTAR; SEVERITY OF ILLNESS INDEX;

EID: 33750930717     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000244808.17972.55     Document Type: Article

References (23)

1. Meguro K, Hatazawa J, Yamaguchi T, Itoh M, Matsuzawa T, Ono S, Miyazawa H, Hishinuma T, Yanai K, Sekita Y. Cerebral circulation and oxygen metabolism associated with subcortical perivascular hyperintensity as shown by magnetic resonance imaging. Ann Neurol. 1990;28:378-383.
2. Wakita H, Tomimoto H, Akiguchi I, Kimura J. Glial activation and white, matter changes in the rat brain induced by chronic cerebral hypoperfusion: an immunohistochemical study. Acta Neuropathol. 1994;87:484-492.
3. Shibata M, Ohtani R, Ihara M, Tomimoto H. White matter lesions and glial activation in a novel mouse model of chronic cerebral hypoperfusion. Stroke. 2004;35:2598-2603.
4. Sternlicht MD, Werb Z. How matric metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463-516.
5. Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett. 1997;238:53-56.
6. Rosenberg GA, Sullivan N, Esiri MM. White matter damage is associated with matrix metalloproteinases in vascular dementia. Stroke. 2001;32:1162-1168.
7. Hamann GF, Okada Y, Fitridge R, del Zoppo GJ. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke. 1995;26:2120-2126.
8. Ihara M, Tomimoto H, Kinoshita M, Oh J, Noda M, Wakita H, Akiguchi I, Shibasaki H. Chronic cerebral hypoperfusion induces MMP-2 but not MMP-9 expression in the microglia and vascular endothelium of the white matter. J Cereb Blood Flow Metab. 2001;21:828-834.
9. Price A, Shi Q, Morris D, Wilcox ME, Brasher PM, Rewcastle NB, Shalinsky D, Zou H, Appelt K, Johnston RN, Yong VW, Edwards D, Forsyth P. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin Cancer Res. 1999;4:845-854.
10. Itoh T, Ikeda T, Gomi H, Nakao S, Suzuki T, Itohara S. Unaltered secretion of beta-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J Biol Chem. 1997;272:22389-22392.
11. Asahi M, Sumii T, Fini ME, Itohara S, Lo EH. Matrix metalloproteinase 2 gene knockout has no effect on acute brain injury after focal ischemia. Neuroreport. 2001;12:3003-3007.
12. Shalinsky DR, Brekken J, Zou H, McDermott CD, Forsyth P, Edwards D, Margosiak S, Bender S, Truitt G, Wood A, Varki NM, Appelt K. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci. 1999;878:236-270.
13. Rosenberg GA, Navratil M, Barone F, Feuerstein G. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab. 1996;16:360-366.
14. Horstmann S, Kalb P, Koziol J, Gardner H, Wagner S. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke. 2003;34:2165-2170.
15. Maier CM, Hsieh L, Yu F, Bracci P, Chan PH. Matrix metalloproteinase-9 and myeloperoxidase expression: quantitative analysis by antigen immunohistochemistry in a model of transient focal cerebral ischemia. Stroke. 2004;5:1169-1174.
16. Lee SR, Tsuji K, Lee SR, Lo EH. Role of matrix metalloproteinase in delayed neuronal damage after transient global ischemia. J Neurosci. 2004;24:671-678.
17. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab. 1999;19:624-633.
18. Esparza J, Kruse M, Lee J, Michaud M, Madri JA. MMP-2 null mice exhibit an early onset and severe experimental autoimmune encephalomyelitis due to an increase in MMP-9 expression and activity. FASEB J. 2004;18:1682-1691.
19. Fukuda S, Fini CA, Mabuchi T, Koziol JA, Eggleston LL Jr, del Zoppo GJ. Focal cerebral ischemia induces active proteases that degrade microvascular matrix. Stroke. 2004;35:998-1004.
20. Chang DI, Hosomi N, Lucero J, Heo JH, Abumiya T, Mazar AP. Activation system for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia. J Cereb Blood Flow Metab. 2003;23:1408-1419.
21. Ueno M, Tomimoto H, Akiguchi I, Wakita H, Sakamoto H. Blood-brain barrier disruption in white matter lesions in a rat model of chronic cerebral hypoperfusion. J Cereb Blood Flow Metab. 2002;22:97-104.
22. Caplan LR. Dilatative arteriopathy (dolichoectasia): what is known and not known. Ann Neurol. 2005;57:472-479.
23. Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett. 1995;201:223-226.